title: Alterations in growth hormone receptor abundance regulate growth hormone signaling in murine obstructive cholestasis.
abstract: Children with cholestatic liver diseases, in particular biliary atresia, may develop an acquired growth hormone (GH) resistance. This is characterized by normal GH secretion, reduced liver GH receptor (GHR) abundance, and reduced circulating insulin-like growth factor I (IGF-I). Consequences include linear growth failure, reduced muscle mass, and increased perioperative morbidity and mortality. However, the molecular basis for altered GH signaling in liver and skeletal muscle in cholestatic liver disease is not known. We hypothesized that reduced IGF-I expression in obstructive cholestasis would be associated with downregulation of the GHR and impaired phosphorylation of signal transducers and activators of transcription (STAT5). Body composition was determined in C57BL/6J male mice after bile duct ligation (BDL) relative to pair-fed (PF) and ad libitum-fed controls. GHR, STAT5, Sp3, and IGF-I expression and/or DNA binding were assessed using immunoblots, electrophoretic mobility shift assays, and/or real time RT-PCR. Fat-free mass was reduced in PF mice relative to ad libitum-fed controls. BDL led to a further reduction in fat mass and fat-free mass relative to PF controls. TNF-alpha was increased in liver and skeletal muscle of BDL mice. This was associated with reduced GH-dependent STAT5 activation and IGF-I RNA expression. GHR expression was reduced in BDL mice; in liver, this was associated with reduced Sp3 binding to a GHR gene promoter cis element. Wasting in murine obstructive cholestasis is due to combined effects of reduced caloric intake and biliary obstruction. GH resistance due to downregulation of GHR expression may be attributed primarily to the obstructive cholestasis; therapies that specifically increase GHR expression may restore GH signaling in this setting.
authors.affiliation: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Held
authors.forename: Wilfredo
authors.initials: W
authors.lastname: Cosme-Blanco
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Difedele
authors.forename: Erin L
authors.initials: EL
authors.lastname: Bonkowski
authors.forename: Ram K
authors.initials: RK
authors.lastname: Menon
authors.forename: Lee A
authors.initials: LA
authors.lastname: Denson
mesh_terms: D000818:Animals; D001823:Body Composition / Q000502:physiology*; D002779:Cholestasis / Q000378:metabolism / Q000503:physiopathology*; D004268:DNA-Binding Proteins / Q000378:metabolism / Q000502:physiology; D015536:Down-Regulation / Q000502:physiology; D005786:Gene Expression Regulation; D006128:Growth / Q000502:physiology*; D013006:Growth Hormone / Q000502:physiology*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008894:Milk Proteins; D018482:Muscle, Skeletal / Q000378:metabolism; D010766:Phosphorylation; D011986:Receptors, Somatotropin / Q000378:metabolism*; D050799:STAT5 Transcription Factor; D051705:Sp3 Transcription Factor; D015534:Trans-Activators / Q000502:physiology; D014157:Transcription Factors / Q000378:metabolism
chemical_list: D004268:DNA-Binding Proteins; D008894:Milk Proteins; D011986:Receptors, Somatotropin; D050799:STAT5 Transcription Factor; C497122:Sp3 protein, mouse; D015534:Trans-Activators; D014157:Transcription Factors; D051705:Sp3 Transcription Factor; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone